Recently Dr. K.K. Aggarwal's eMedinewS has published the letter of Dr. Piyali Datta Chakraborty (who is a part of IICB team working on Human Placental Extract research in India). Dr. R S Bajaj from Delhi as a reader to that post, responded to this on the 27th March 2011 issue of eMediNewS. We wish to share his feedback with our readers, and our sincere courtesy to Dr. K.K. Aggarwal's eMedinewS for this.
Dr R S Bajaj says:
Dear Dr Agarwal, This is in reference to the letter by Dr. Piyali Datta Chakraborty, Ph.D. (Science) regarding the ban on Placentrax (24th March Issue). I fully endorse her views. The working of Drug Controller of India needs more transparency. The procedure of approval of a drug or banning of a drug needs to be clearly defined. What we are seeing now is ‘adhocism’. If the media highlights a thing, immediately there is a knee jerk reaction. I remember few years back one of the medical representative came to me and asked me to give a letter for making Nimesulide drops available in the market. On further questioning I was told that Drug Controller of India needs 50 such letters by paediatricains to grant approval. I refused to give such a letter. But after few months I found that drops are available! I wish before granting approval to a drug, the opinion of specialist bodies like API/IAP and other professional bodies like ICMR is taken The procedure should be published on the website of Drug Controller of India and the opinion given by such bodies should also be published. Sincerely, Dr R S Bajaj, Consultant Paediatrician, Rohini.
No comments:
Post a Comment